Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q1 2015 (← Previous) (Next →)

Filing Date: Apr 23, 2015

Total Value: $113.7B (100.0% shares, 0.0% debt)

Holdings (6)

— Clovis Oncology, Inc. 53.2%

Value $60.49B Shares 814,833 Est. Cost $56000.00 Unrealized —

— Five Prime Therapeutics, Inc. 21.9%

Value $24.96B Shares 1,092,152 Est. Cost $27000.00 Unrealized —

— Achaogen, Inc. 11.0%

Value $12.5B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— CymaBay Therapeutics, Inc. 6.4%

Value $7.256B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

INGN Inogen, Inc. 4.4%

Value $4.968B Shares 155,284 Est. Cost $32.28 Unrealized 0.0%

— Kythera Biopharmaceuticals, Inc. 3.1%

Value $3.529B Shares 70,376 Est. Cost $34680.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Clovis Oncology, Inc.	814,833	$60.49B	53.2%	$56000.00	—	Common Stock	189464100
—	Five Prime Therapeutics, Inc.	1,092,152	$24.96B	21.9%	$27000.00	—	Common Stock	33830X104
—	Achaogen, Inc.	1,281,152	$12.5B	11.0%	$13050.00	—	Common Stock	004449104
—	CymaBay Therapeutics, Inc.	1,048,601	$7.256B	6.4%	$9830.00	—	Common Stock	23257D103
INGN	Inogen, Inc.	155,284	$4.968B	4.4%	$32.28	0.0%	Common Stock	45780L104
—	Kythera Biopharmaceuticals, Inc.	70,376	$3.529B	3.1%	$34680.00	—	Common Stock	501570105